Can Omada do a Livongo?
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
Teleflex recommits to takeovers
In a time of unpredictable demand for its products, the diversified medtech is unafraid to acquire.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Balancing the accuracy and cost of antigen testing
Antigen tests for Covid-19 can be useful if used in the right settings, but those settings are expensive.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
